Rhythm Pharmaceuticals (RYTM)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Key Insights
Critical company metrics and information
Share Price
$60.37Market Cap
$3.71 BillionTotal Outstanding Shares
61.46 Million SharesTotal Employees
226Dividend
No dividendIPO Date
October 5, 2017SIC Description
Pharmaceutical PreparationsHomepage
http://www.rhythmtx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-113.54 Million |
| Net Cash Flow From Investing Activities | $-90.82 Million |
| Net Cash Flow | $-113.54 Million |
| Net Cash Flow From Investing Activities, Continuing | $-90.82 Million |
| Net Cash Flow From Financing Activities | $2.49 Million |
| Net Cash Flow From Financing Activities, Continuing | $2.49 Million |
| Net Cash Flow From Operating Activities, Continuing | $-25.21 Million |
| Net Cash Flow From Operating Activities | $-25.21 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Gross Profit | $29.42 Million |
| Nonoperating Income/Loss | $100000.00 |
| Revenues | $33.25 Million |
| Income/Loss From Continuing Operations Before Tax | $-43.98 Million |
| Benefits Costs and Expenses | $77.24 Million |
| Diluted Average Shares | $61.22 Million |
| Basic Average Shares | $61.22 Million |
| Operating Expenses | $73.31 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $1.33 Million |
| Costs And Expenses | $77.14 Million |
| Research and Development | $37.93 Million |
| Net Income/Loss | $-43.64 Million |
| Operating Income/Loss | $-43.88 Million |
| Basic Earnings Per Share | $0.73 |
| Selling, General, and Administrative Expenses | $35.38 Million |
| Preferred Stock Dividends And Other Adjustments | $1.33 Million |
| Income Tax Expense/Benefit | $344000.00 |
| Diluted Earnings Per Share | $0.73 |
| Net Income/Loss Attributable To Parent | $-43.64 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-44.97 Million |
| Cost Of Revenue | $3.83 Million |
| Income/Loss From Continuing Operations After Tax | $-43.64 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Equity | $11.21 Million |
| Accounts Payable | $4.89 Million |
| Other Current Assets | $28.06 Million |
| Cash | $298.39 Million |
| Noncurrent Assets | $23.23 Million |
| Other Current Liabilities | $92.72 Million |
| Equity Attributable To Parent | $11.21 Million |
| Assets | $363.57 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Current Assets | $340.34 Million |
| Temporary Equity | $141.48 Million |
| Noncurrent Liabilities | $113.27 Million |
| Fixed Assets | $801000.00 |
| Other Non-current Assets | $22.43 Million |
| Liabilities | $210.88 Million |
| Temporary Equity Attributable To Parent | $141.48 Million |
| Liabilities And Equity | $363.57 Million |
| Inventory | $13.89 Million |
| Current Liabilities | $97.61 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.